Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Key Points

• Stifel Nicolaus raised Glaukos’ price target to $225 from $190 and maintained a “buy” rating, implying roughly 24% upside from the prior close. Analysts overall rate the stock “Moderate Buy,” with an average target of $194.93.
• Glaukos reported a strong quarter, with revenue rising 58% year over year to $211.03 million and adjusted EPS of $0.47, well above the expected loss of $0.10 per share.
• Insider selling and elevated valuation remain risks: insiders sold about $15 million of stock over 90 days, while the shares trade near their 52-week high despite negative trailing profitability metrics.

Glaukos (NYSE:GKOS - Get Free Report) had its price objective hoisted by equities research analysts at Stifel Nicolaus from $190.00 to $225.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the medical instruments supplier's stock. Stifel Nicolaus's target price would suggest a potential upside of 23.99% from the stock's previous close.

Several other analysts also recently issued reports on the company. HC Wainwright upped their price target on Glaukos from $168.00 to $195.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Wall Street Zen upgraded Glaukos from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Glaukos in a research report on Thursday, October 15th. Wells Fargo & Company upped their target price on Glaukos from $138.00 to $178.00 and gave the stock an "overweight" rating in a research report on Thursday, July 30th. Finally, Truist Financial set a $255.00 price target on Glaukos in a report on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $194.93.

Glaukos Stock Up 0.2%

GKOS stock opened at $181.47 on Thursday. The firm has a market cap of $10.70 billion, a PE ratio of -55.84 and a beta of 0.69. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The firm has a 50 day simple moving average of $171.24 and a 200 day simple moving average of $139.87. Glaukos has a 12 month low of $76.88 and a 12 month high of $191.62.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The firm had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. During the same period last year, the company posted ($0.16) EPS. The business's quarterly revenue was up 58.0% compared to the same quarter last year. Equities research analysts forecast that Glaukos will post -0.32 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In other Glaukos news, Director Leana Wen sold 525 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $167.63, for a total value of $88,005.75. Following the completion of the sale, the director owned 21,092 shares in the company, valued at approximately $3,535,651.96. This trade represents a 2.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joseph Gilliam sold 60,000 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares in the company, valued at $13,046,967.12. This trade represents a 45.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 83,025 shares of company stock valued at $14,950,006. Company insiders own 5.90% of the company's stock.

Hedge Funds Weigh In On Glaukos

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Stephens Inc. AR acquired a new stake in Glaukos during the 1st quarter worth approximately $363,000. Quantinno Capital Management LP boosted its holdings in shares of Glaukos by 964.0% in the first quarter. Quantinno Capital Management LP now owns 30,836 shares of the medical instruments supplier's stock valued at $3,320,000 after buying an additional 27,938 shares during the period. TimesSquare Capital Management LLC acquired a new position in shares of Glaukos in the second quarter valued at approximately $20,293,000. BlackRock Inc. bought a new stake in shares of Glaukos during the second quarter worth $1,333,318,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Glaukos during the second quarter worth $3,361,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record revenue beat expectations: Third-quarter revenue increased approximately 58% year over year to $211.0 million, exceeding the $168.0 million consensus estimate. Gross profit rose to $179.9 million. Glaukos Corporation Reports Third-Quarter Earnings
• Positive Sentiment: Profitability materially outperformed forecasts: Glaukos reported adjusted earnings of $0.47 per share, compared with analysts’ expected loss of approximately $0.10–$0.12 per share and a year-ago loss of $0.16. GAAP net income attributable to common shareholders was $2.0 million, or $0.03 per diluted share, marking a return to profitability. Glaukos Q3 Earnings and Revenue Results
• Positive Sentiment: Full-year guidance was sharply increased: Management raised 2026 net-sales guidance to $775 million–$785 million from $680 million–$700 million. It also introduced a preliminary 2027 sales target of approximately $1 billion, signaling confidence in sustained demand and product adoption. Glaukos Raises Sales Outlook
• Positive Sentiment: Cash generation remained solid: Operating activities generated $14.8 million, while Glaukos ended the quarter with $162.3 million in cash and cash equivalents and modest capital spending of $2.7 million.
• Neutral Sentiment: Investor expectations are elevated: The stock is near its 52-week high, while the reported P/E remains negative and the company continues to post negative trailing profitability metrics. Continued execution will be necessary to support the higher valuation.
• Negative Sentiment: Insider selling is a potential overhang: Company insiders reported 32 open-market sales and no purchases during the past six months. In addition, the median analyst price target cited in the provided reports was $165, below the current share-price range.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company's principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.